Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance

A. E. Pontiroli, M. G. Perfetti, G. Pozza

Research output: Contribution to journalArticlepeer-review

Abstract

Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.

Original languageEnglish
Pages (from-to)32-34
Number of pages3
JournalHormone and Metabolic Research, Supplement
Issue number26
Publication statusPublished - 1992

Keywords

  • C-peptide
  • diabetes
  • glipizide
  • impaired glucose tolerance
  • insulin
  • obesity
  • sulfonylureas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Fingerprint Dive into the research topics of 'Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance'. Together they form a unique fingerprint.

Cite this